TRCT
ABVC icon

Tower Research Capital (TRC)’s ABVC BioPharma ABVC Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,423
Closed -$5.26K – 5181
2026
Q1 		$5.26K Buy
5,423
+2,230
+70% +$3.69K ﹤0.01% 4130
2025
Q4 		$6.8K Buy
3,193
+1,038
+48% +$2.78K ﹤0.01% 4048
2025
Q3 		$6.55K Buy
2,155
+1,801
+509% +$5.53K ﹤0.01% 4152
2025
Q2 		$788 Sell
354
-2,222
-86% -$3.02K ﹤0.01% 4943
2025
Q1 		$2.73K Buy
2,576
+13
+0.5% +$8 ﹤0.01% 4515
2024
Q4 		$1.51K Sell
2,563
-60
-2% -$33 ﹤0.01% 5005
2024
Q3 		$1.79K Sell
2,623
-23
-0.9% -$17 ﹤0.01% 5100
2024
Q2 		$2.05K Buy
2,646
+126
+5% +$129 ﹤0.01% 5060
2024
Q1 		$3.3K Buy
2,520
+1,942
+336% +$2.52K ﹤0.01% 4887
2023
Q4 		$670 Sell
578
-2,407
-81% -$2.84K ﹤0.01% 5515
2023
Q3 		$3.1K Buy
2,985
+1,597
+115% +$3.86K ﹤0.01% 5052
2023
Q2 		$7.22K Buy
1,388
+63
+5% +$419 ﹤0.01% 4606
2023
Q1 		$8K Sell
1,325
-100
-7% -$714 ﹤0.01% 4603
2022
Q4 		$9K Sell
1,425
-85
-6% -$628 ﹤0.01% 4146
2022
Q3 		$13K Buy
1,510
+910
+152% +$7.65K ﹤0.01% 4250
2022
Q2 		$6K Buy
+600
New +$12.1K ﹤0.01% 4886
2021
Q4 		– Sell
-349
Closed -$8K – 6091
2021
Q3 		$8K Buy
+349
New +$9.88K ﹤0.01% 4512

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ABVC Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of ABVC BioPharma (ABVC) in Q2 2026, closing a stake of 5,423 shares — an estimated $5.26K sold.

Tower Research Capital (TRC) first reported a position in ABVC in Q3 2021 and held it in 17 quarters. The position peaked at $13K in Q3 2022. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining ABVC BioPharma position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,423 ABVC BioPharma shares in Q2 2026, an estimated $5.26K.
  • Tower Research Capital (TRC) first reported a position in ABVC BioPharma in Q3 2021 and held it in 17 quarters.
  • Tower Research Capital (TRC)'s ABVC BioPharma position peaked at $13K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.